Baird Financial Group
KPTI icon

Baird Financial Group’s Karyopharm Therapeutics KPTI Stock Holding History

Baird Financial Group’s Portfolio KPTI Stock Details KPTI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$291K Hold
29,791
– – ﹤0.01% 1741
2026
Q1 		$166K Buy
29,791
+1,798
+6% +$13.7K ﹤0.01% 1793
2025
Q4 		$206K Buy
27,993
+2,061
+8% +$12.6K ﹤0.01% 1730
2025
Q3 		$170K Buy
25,932
+15,400
+146% +$82.9K ﹤0.01% 1747
2025
Q2 		$45.4K Buy
+10,532
New +$51.7K ﹤0.01% 1758
2025
Q1 		– Sell
-2,987
Closed -$30.3K – 1802
2024
Q4 		$30.3K Buy
2,987
+467
+19% +$5.65K ﹤0.01% 1742
2024
Q3 		$31.4K Buy
2,520
+67
+3% +$833 ﹤0.01% 1735
2024
Q2 		$31.9K Buy
2,453
+1,066
+77% +$17.6K ﹤0.01% 1741
2024
Q1 		$31.4K Buy
1,387
+467
+51% +$8.19K ﹤0.01% 1739
2023
Q4 		$11.9K Hold
920
– – ﹤0.01% 1702
2023
Q3 		$18.5K Hold
920
– – ﹤0.01% 1698
2023
Q2 		$24.7K Sell
920
-878
-49% -$37.8K ﹤0.01% 1676
2023
Q1 		$105K Buy
1,798
+525
+41% +$25.9K ﹤0.01% 1655
2022
Q4 		$65K Buy
1,273
+60
+5% +$4.16K ﹤0.01% 1665
2022
Q3 		$99K Buy
1,213
+85
+8% +$6.35K ﹤0.01% 1669
2022
Q2 		$76K Sell
1,128
-8
-0.7% -$734 ﹤0.01% 1752
2022
Q1 		$126K Sell
1,136
-185
-14% -$23.1K ﹤0.01% 1775
2021
Q4 		$127K Buy
1,321
+142
+12% +$14.2K ﹤0.01% 1848
2021
Q3 		$103K Buy
1,179
+48
+4% +$4.98K ﹤0.01% 1841
2021
Q2 		$175K Buy
1,131
+90
+9% +$13.1K ﹤0.01% 1706
2021
Q1 		$164K Buy
1,041
+14
+1% +$2.95K ﹤0.01% 1655
2020
Q4 		$239K Buy
1,027
+91
+10% +$21.1K ﹤0.01% 1452
2020
Q3 		$205K Buy
936
+44
+5% +$10.8K ﹤0.01% 1404
2020
Q2 		$253K Buy
892
+29
+3% +$8.58K ﹤0.01% 1356
2020
Q1 		$249K Sell
863
-4
-0.5% -$1.1K ﹤0.01% 1260
2019
Q4 		$249K Buy
+867
New +$188K ﹤0.01% 1393

Other funds holding KPTI

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $366M AUM 474.6% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
CCM
Catalio Capital Management New York $532M AUM 171.17% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Baird Financial Group's KPTI Position: Q2 2026 in Review

Baird Financial Group held its Karyopharm Therapeutics (KPTI) position steady in Q2 2026 at 29,791 shares worth $291K. The position accounts for ﹤0.01% of the portfolio, ranked #1741.

Baird Financial Group first reported a position in KPTI in Q4 2019 and has held it in 26 quarters since. 97 funds tracked by Wall St. Rank hold KPTI as of Q2 2026.

  • Baird Financial Group held 29,791 shares of Karyopharm Therapeutics worth $291K as of Q2 2026.
  • Baird Financial Group left its Karyopharm Therapeutics share count unchanged in Q2 2026.
  • Karyopharm Therapeutics made up ﹤0.01% of Baird Financial Group's portfolio in Q2 2026, its #1741 holding.
  • Baird Financial Group first reported a position in Karyopharm Therapeutics in Q4 2019 and has held it in 26 quarters since.
  • 97 funds tracked by Wall St. Rank held Karyopharm Therapeutics as of Q2 2026.

Based on Baird Financial Group's 13F filing for Q2 2026, filed 12 Aug 2026.